RNAZ
TransCode Therapeutics, Inc.·Healthcare
8.21
3.977%(−0.34)
Market ClosedLast Updated: — ET
52W L: $6.0852W H: $22.04
RNAZ NEWS
prnewswire.com
4d ago
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an agreement with an institutional healthcare investor for financing of up to $20 million. The arrangement comprises pre-paid advances of up to $6 million and a three-year Standby Equity Purchase Agreement (SEPA) providing the Company the right to sell up to $14 million of its common stock to the investor, subject to certain conditions.
defenseworld.net
Apr 3
4D Molecular Therapeutics (NASDAQ:FDMT) versus TransCode Therapeutics (NASDAQ:RNAZ) Head-To-Head Contrast
TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and 4D Molecular Therapeutics (NASDAQ: FDMT - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk. Insider and Institutional Ownership 99.3% of
defenseworld.net
Mar 15
Head-To-Head Comparison: Karyopharm Therapeutics (NASDAQ:KPTI) & TransCode Therapeutics (NASDAQ:RNAZ)
TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and Karyopharm Therapeutics (NASDAQ: KPTI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk. Valuation and Earnings This table compares TransCode
prnewswire.com
Mar 3
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer. BOSTON, March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash").
prnewswire.com
Feb 23
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
BOSTON, Feb. 23, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a manuscript titled Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy in the journal Molecular Imaging and Biology. The paper, published February 19, 2026, reports on a novel tumor-selective immunotherapy approach that activates innate immune signaling specifically within cancer cells while enabling non-invasive imaging of drug delivery.
prnewswire.com
Feb 5
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, in collaboration with Quantum Leap Healthcare Collaborative (Quantum Leap), today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application amendment for a planned Phase 2a clinical trial with TransCode's lead therapeutic candidate, TTX-MC138. The study will be conducted by Quantum Leap within their PRE-I-SPY program, a leading platform for innovative oncology clinical trials, and represents the program's first expansion into colorectal cancer.
